4.19
+0.18(+4.49%)
Currency In USD
Previous Close | 4.01 |
Open | 4.01 |
Day High | 4.2 |
Day Low | 4.01 |
52-Week High | 28.6 |
52-Week Low | 3.91 |
Volume | 15,662 |
Average Volume | 111,393 |
Market Cap | 2.95M |
PE | -0.22 |
EPS | -18.93 |
Moving Average 50 Days | 6.53 |
Moving Average 200 Days | 7.51 |
Change | 0.18 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $0 as of October 19, 2025 at a share price of $undefined. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $0 as of October 19, 2025 at a share price of $undefined.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
GlobeNewswire Inc.
Oct 15, 2025 1:15 PM GMT
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treate
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derma
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm